Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | PGK1 | P00558 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | WHR1 | P49842 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.41 |
| ▸ | TUBB | P07437 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29636842 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2ALDH1A1PDE3BPDE3AKDM4E | |
| SCHEMBL20588239 | 0.87 | NQO2 (0.39) | SMN1; SMN2ALDH1A1PDE3BPDE3AKDM4E | |
| SCHEMBL1699128 | 0.87 | DHFR (0.40) | SMN1; SMN2ALDH1A1PDE3BPDE3AKDM4E | |
| SCHEMBL18788167 | 0.86 | PDPK1 (0.46) | SMN1; SMN2ALDH1A1KDM4EACHEPOLB | |
| SCHEMBL15647874 | 0.86 | EGFR (0.38) | SMN1; SMN2ALDH1A1PDE3BPDE3AKDM4E | |
| SCHEMBL28499601 | 0.86 | AXL (0.38) | SMN1; SMN2ALDH1A1PDE3BPDE3AHTT | |
| SCHEMBL17372498 | 0.86 | KDR (0.42) | SMN1; SMN2ALDH1A1KDM4EHTTPOLB | |
| SCHEMBL17372657 | 0.84 | ENPP1 (0.45) | SMN1; SMN2ALDH1A1KDM4EHTTEGFR | |
| SCHEMBL17372585 | 0.83 | MAPT (0.56) | SMN1; SMN2ALDH1A1PDE3BPDE3AKDM4E | |
| SCHEMBL28894255 | 0.83 | ACHE (0.46) | SMN1; SMN2ALDH1A1PDE3BPDE3AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220388962-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 2022-12-08 | — | — | US | disclosed |
| CN-115362150-A | ENPP1 inhibitor, composition and application thereof | 贝达药业股份有限公司 | 2022-11-18 | — | — | CN | disclosed |
| EP-4017492-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | Biohaven Therapeutics Ltd. (US) | 2022-06-29 | — | — | EP | disclosed |
| CN-114667145-A | Molecules that bind to TDP-43 for the treatment of amyotrophic lateral sclerosis and related disorders | 拜尔哈文制药股份有限公司 | 2022-06-24 | — | — | CN | disclosed |
| EP-3906234-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | Array BioPharma Inc. (US) | 2021-11-10 | — | — | EP | disclosed |
| CN-113302188-A | Quinoline compounds as TAM and MET kinase inhibitors | 阵列生物制药公司 | 2021-08-24 | — | — | CN | disclosed |
| EP-2938608-B1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | SANFORD BURNHAM MED RES INST (US) | 2021-08-04 | — | — | EP | disclosed |
| WO-2021035101-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-02-25 | — | — | WO | disclosed |
| WO-2020141470-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC. (US) | 2020-07-09 | — | — | WO | disclosed |
| US-20200216416-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC. (US) | 2020-07-09 | — | — | US | disclosed |
| US-7615552-B2 | Fused heterocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2009-11-10 | — | — | US | disclosed |
| US-7615552-B2 | Fused heterocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2009-11-10 | — | — | US | disclosed |
| US-20090253694-A1 | Fused hetrocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090253694-A1 | Fused hetrocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090253694-A1 | Fused hetrocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2009-10-08 | — | — | US | disclosed |
| EP-1687002-A4 | FUSED HETEROCYCLIC COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1687002-A1 | FUSED HETEROCYCLIC COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20050250770-A1 | Fused heterocyclic compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | disclosed |
| WO-2005046698-A1 | FUSED HETEROCYCLIC COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2003055866-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVE COMPOUNDS AS INHIBITORS OF PROLYLPEPTIDASE, INDUCERS OF APOPTOSIS AND CANCER TREATMENT AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250770-A1 | Fused heterocyclic compounds | IL2, IL4, IL15 | SMN1; SMN2 1865/4885ALDH1A1 842/4885PDE3B 2069/4885 |
| US-20090253694-A1 | Fused hetrocyclic compounds | IL2, IL15, IL4 | SMN1; SMN2 2900/4885ALDH1A1 1338/4885PDE3B 2024/4885 |
| US-20220388962-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | TARDBP, TDP1, TDP2 | SMN1; SMN2 87/4885ALDH1A1 4077/4885PDE3B 4626/4885 |
| US-20200216416-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | RET, MET, MERTK | SMN1; SMN2 4182/4885ALDH1A1 2830/4885PDE3B 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.